Understanding intratumoral heterogeneity—the molecular variation among cells within a
tumor—promises to address outstanding questions in cancer biology and improve the …

Ductal carcinoma in situ (DCIS) now represents 20–25% of all 'breast cancers' consequent
upon detection by population-based breast cancer screening programmes. Currently, all …

Spatial Transcriptomics is an emerging technology that adds spatial dimensionality and
tissue morphology to the genome-wide transcriptional profile of cells in an undissociated …

Ductal carcinoma in situ (DCIS) is the most common form of preinvasive breast cancer and,
despite treatment, a small fraction (5–10%) of DCIS patients develop subsequent invasive …

Ductal carcinoma in situ (DCIS) is a nonobligate precursor of invasive cancer, and its
detection, diagnosis, and management are controversial. DCIS incidence grew with the …

Ductal carcinoma in situ (DCIS) is a common precursor of invasive breast cancer. Our
understanding of its genomic progression to recurrent disease remains poor, partly due to …

Cancer growth can be described as a caricature of the renewal process of the tissue of
origin, where the tissue architecture has a strong influence on the evolutionary dynamics …

Immunotherapy using checkpoint inhibitors is one of the most promising current cancer
treatment strategies. However, in breast cancer, its success has been limited to a subset of …

Breast cancer is one of the most common cancers affecting women. Despite significant
improvements in overall survival, it remains a significant cause of death worldwide. Genomic …

Purpose: Ductal carcinoma in situ (DCIS) is a nonobligate precursor of invasive breast
cancer. Here, we sought to investigate the level of intralesion genetic heterogeneity in DCIS …